SCHEMBL123451

SCHEMBL123451

O=c1[nH]c2cc(F)c(F)cc2[nH]c1=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.58
GRIN2D O15399 14/20 0.55
GRIN3B O60391 14/20 0.55
GRIN1 Q05586 14/20 0.55
GRIN2A Q12879 14/20 0.55
GRIN2B Q13224 14/20 0.55
GRIN2C Q14957 14/20 0.55
GRIN3A Q8TCU5 14/20 0.55
GRIA1 P42261 3/20 0.55
GRIA2 P42262 3/20 0.55
GRIA3 P42263 3/20 0.55
GRIA4 P48058 3/20 0.55
LMNA P02545 2/20 0.55
CYP1A2 P05177 2/20 0.55
MAPT P10636 2/20 0.55
HPGD P15428 2/20 0.55
TSHR P16473 2/20 0.55
BLM P54132 2/20 0.55
MEN1 O00255 1/20 0.55
ALDH1A1 P00352 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL463673 0.83 GRIN2D (0.52) KDM4EGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL3786399 0.82 PDE3B (0.50) KDM4EGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL30807513 0.81 GRIN2D (0.67) KDM4EGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL30807512 0.81 GRIN2D (0.67) KDM4EGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL121242 0.74 KDM4E (1.00) KDM4EGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL8296947 0.73 GRIA1 (0.49) KDM4EGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL31378692 0.73 GRIN2D (0.39) KDM4EGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL7346405 0.71 GRIN2D (1.00) KDM4EGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL2639553 0.71 GRIN2D (0.73) KDM4EGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL3426314 0.71 KDM4E (0.53) KDM4EGRIN2DGRIN3BGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114907328-B Organic photocatalyst based on quinoxaline skeleton, and preparation method and application thereof 兰州大学 2023-12-26 CN claimed
US-20240339644-A1 Symmetric Redox Molecules Using Synergistic Electron Directing Pairs ExxonMobil Technology and Engineering Company (US) 2024-10-10 US disclosed
CN-114907328-B Organic photocatalyst based on quinoxaline skeleton, and preparation method and application thereof 兰州大学 2023-12-26 CN disclosed
CN-114907328-A Quinoxaline framework based organic photocatalyst and preparation method and application thereof 兰州大学 2022-08-16 CN disclosed
EP-2424537-B1 SUBSTITUTED IMIDAZOQUINOXALINES BAYER IP GMBH (DE) 2015-07-08 EP disclosed
EP-2424537-B1 SUBSTITUTED IMIDAZOQUINOXALINES BAYER IP GMBH (DE) 2015-07-08 EP disclosed
US-8729082-B2 Substituted imidazoquinoxalines BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-05-20 US disclosed
US-8729082-B2 Substituted imidazoquinoxalines BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-05-20 US disclosed
US-8729082-B2 Substituted imidazoquinoxalines BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-05-20 US disclosed
US-20120128662-A1 SUBSTITUTED IMIDAZOQUINOXALINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-05-24 US disclosed
WO-2010124826-A1 SUBSTITUTED IMIDAZOQUINOXALINES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-11-04 WO disclosed
EP-0647137-B1 GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF UNIV CALIFORNIA (US) 2008-08-13 EP disclosed
US-6251903-B1 Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonist COCENSYS, INC. 2001-06-26 US disclosed
US-6147075-A ANALGESICS; PSYCHOLOGICAL DISORDERS COCENSYS, INC. (US) 2000-11-14 US disclosed
US-5977107-A Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonists COCENSYS, INC. (US) 1999-11-02 US disclosed
US-5631373-A NERVOUS SYSTEM DISORDERS STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) 1997-05-20 US disclosed
US-5622952-A NERVOUS SYSTEM DISORDERS; ADMINISTERING 1,4-DIHYDROQUINOXALINE-2,3-DIONE STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) 1997-04-22 US disclosed
US-5620979-A TREATING NEURONAL LOSS ASSOCIATED WITH STROKE, ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA OR SURGERY STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) 1997-04-15 US disclosed
US-5514680-A ANTICONVULSANTS WITH 5,6,7-TRISUBSTITUTED-1,4-DIHYDROQUINOXALINE-2,3-DIONE THE STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY (US) 1996-05-07 US disclosed
WO-1994000124-A1 GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF WEBER ECKARD (US) 1994-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120128662-A1 SUBSTITUTED IMIDAZOQUINOXALINES TTBK1, TTK, TTBK2 KDM4E 4230/4885GRIN2D 4552/4885GRIN3B 3912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.